1. The Experimental Study of rALR on Immunologic Response Induced by Exogenous Antigen in Rat 2. Analysis on Cause of Death in 115 Patients with Hepatic Failure Induced by Viral Hepatitis 3. The Primary Clinical Study of Peginterferon Alfa-2a in the Treatment the Patients with HBeAg-Positive Chronic Hepatitis B and with Drug Fast to Lamivudine
1.肝再生增强因子对外原性抗原引起机体免疫应答影响的初步研究 2.病毒性肝炎肝衰竭患者死亡原因分析 3.聚乙二醇化干扰素α-2a治疗HBeAg阳性的慢性乙型肝炎及其应用于 拉米夫定耐药的初步临床观察
1.Clinic Study on the Adefovir Dipivoxil Treat Patients with HBeAg(+) Hepatitis B Resistant to Lamivudine 2.Preliminary Study on the Effect of Severe Hepatitis Plasma on Umbilical Cord Blood Mesenchymal Stem Cells in Vitro
1.阿德福韦酯治疗 拉米夫定耐药HBeAg（+）慢性乙肝的临床研究 2.重型肝炎患者血浆对体外培养脐血间充质干细胞影响的初步研究
However,22.8% of patients in the control group had YMDD variant HBV as compared with 3.03% in the treated group,and P value was <0.05.Conclusion:Thymosin-α1 combined with Lamivudine is effective for the patients with chronic hepatitis B and is valuable to be used in clinical.
HBV YMDD变异株:治疗组仅有1例(3.03%),对照组有8例(22.8%),两组比较,差异有统计学意义(P<0.05)。 结论: 拉米夫定联合胸腺肽α1治疗慢性乙型肝炎疗效较好,值得临床应用。
METHODS 360 patients with lamivudine was measured by gene-chip,ELISA and autobiological analyzer.
The dosage in the entecavir group and lamivudine group was 0.5 mg/d and 100 mg/d, respectively, and the duration of therapy was 48～96 weeks.
恩替卡韦组与 拉米夫定组的剂量分别为0.5mg/d和100mg/d。 疗程为48～96周。
[Objective] To explore the relationship between YMDD motif mutation, hepatitis B viral loads and alanine aminotransferase (ALT) levels during Lamivudine therapy for chronic hepatitis B. [Methods] 140 chronic hepatitis B patients receiving 48~96 weeks Lamivudine therapy were studied.
目的探讨 拉米夫定治疗慢性乙型肝炎引起的HBVYMDD变异与HBVDNA病毒载量与血清谷丙转氨酶(ALT)之间的关系。 方法140例 拉米夫定治疗48￣96周的慢性乙型肝炎患者为研究对象。
Preliminary trial of lamivudine therapy for chronic HBV infection
Advance on Lamivudine Therapy for Chronic Hepatitis B
Early Hepatitis B e Antigen Seroconversion after Lamivudine Therapy in Patients with Chronic Hepatitis B
Clinical observation of lamivudine therapy in 50 patients with chronic hepatitis B infection
Objective To investigate changes in serum IFN-γand IL-4 levels of patients with chronic hepatitis B during lamivudine treatment.
OBSERVING THE CLINICAL EFFECT OF LAMIVUDINE TREATMENT IN 32 CASES OF CHRONIC HEPATITIS B
Influence of HBV mutation during lamivudine treatment on clinical prognosis of chronic hepatitis B
Th_1/Th_2-type Cytokines Produced by PBMC in Chronic Hepatitis B Patients during Lamivudine Treatment
Preliminary efficacy of lamivudine treatment in patients with hepatitis Be antigen negative chronic HBV infection
Clinical Observation of Treating Patient With Chronic Hepatitis B Using Lamivudine Combined With Marine Injection
Efficacy of treating chronic hepatitis B using lamivudine combining with thymosin α_1
Relationship between the Antiviral Effect and Changes in Helper T(Th) Cytokine Levels in the Treatment of Chronic Hepatitis B Using Lamivudine Combined with Alpha Interferon
but there was no significant difference between the rate of HBV YMDD mutations in the not using lamivudine group and the combination treatment group(x2=2.35, P>0.05).
而未用 拉米夫定组与联用 拉米夫定／干扰素组的HBV－YMDD变异发生率无显著性差异（x2＝2．35，P＞0．05）。
Conclusion Treating chronic hepatitis B using lamivudine combining with thymosin α 1 has a coordinated effect.
结论 拉米夫定与胸腺肽α1 联合应用治疗慢性乙型肝炎的确具有协同作用 ,明显优于单用 拉米夫定治疗慢性乙型肝炎
我想查看译文中含有： 查询“拉米夫定”译词为用户自定义的双语例句 的双语例句
Rapid titrimetric and spectrophotometric assay methods for the determination of lamivudine in pharmaceuticals using iodate and t
In titrimetry, an aqueous solution of lamivudine is titrated directly with iodate in an acidic medium, and in the presence of an excess of bromide using methyl orange as an indicator.
In all methods, the amount of iodate which reacted corresponds to the amount of lamivudine content.
The methods were successfully applied to the assay of lamivudine in tablet form and the results were compared with those of a reference method by applying the Student's t-test and F-test.
Disease progression to AIDS was associated with ?4 and ?2, most evident for zidovudine- lamivudine regimens without a protease inhibitor (P = 0.03); and, 3.
Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy
Objective: To study the clinical features of chronic hepatitis B (CHB) patients with tyrosine-methionine-aspartate-aspartate (YMDD) mutation after lamivudine therapy.
Methods: This investigation was a retrospective study of 63 CHB patients with YMDD mutation during lamivudine therapy.
Results: YMDD mutation occurred 7:_44 months (median, 21.5 months) after the start of lamivudine therapy.
This subset of patients might have benefited from the continued lamivudine therapy.
As several studies on the use of lamivudine for hepatitis B show, the development of resistance in the viral polymerase under lamivudine treatment, however, causes a significant clinical problem.
After successful combined kidney/liver transplantation the patient became HBsAg and HBV DNA (detected by PCR) negative under continuous hyperimmune globulin and lamivudine treatment.
Lamivudine treatment (100?mg/day) was started and clearance of HBsAg was documented 1 year later.
Lamivudine treatment (100?mg daily) resulted in rapid loss of hepatitis B virus DNA, resolution of hepatitis, and clinical recovery.
Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with n
New treatments using lamivudine and other nucleoside analogues such as famciclovir, lobucavir, and adfovir showed promising results although sustained suppression of viral replication is unusual after discontinuation of therapy.
Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature